Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors
Crossref DOI link: https://doi.org/10.1007/s40264-017-0622-2
Published Online: 2017-12-02
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Verden, Abril
Dimbil, Mo
Kyle, Robert
Overstreet, Brian
Hoffman, Keith B.
License valid from 2017-12-02